EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Therapeutic Role of Synthetic Lethality in ARID1A -Deficient Malignancies

Kyaw Z Hein, Bettzy Stephen, Siqing Fu

Journal of Immunotherapy and Precision Oncology · 01.02.2024 · 7 (1) · 41-52

DOI: 10.36401/jipo-22-37 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Immunotherapy and Precision Oncology, online erschienen am 05.02.2024. Verfasst von Kyaw Z Hein und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, HCA Florida Westside Hospital, Plantation, FL, USA. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 157 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

AT-rich interaction domain 1A (ARID1A), a mammalian switch/sucrose nonfermenting complex subunit, modulates several cellular processes by regulating chromatin accessibility. It is encoded by ARID1A, an immunosuppressive gene frequently disrupted in a many tumors, affecting the proliferation, migration, and invasion of cancer cells. Targeting molecular pathways and epigenetic regulation associated with ARID1A loss, such as inhibiting the PI3K/AKT pathway or modulating Wnt/β-catenin signaling, may help suppress tumor growth and progression. Developing epigenetic drugs like histone deacetylase or DNA methyltransferase inhibitors could restore normal chromatin structure and function in cells with ARID1A loss. As ARID1A deficiency correlates with enhanced tumor mutability, microsatellite instability, high tumor mutation burden, increased programmed death-ligand 1 expression, and T-lymphocyte infiltration, ARID1A-deficient cells can be a potential therapeutic target for immune checkpoint inhibitors that warrants further exploration. In this review, we discuss the role of ARID1A in carcinogenesis, its crosstalk with other signaling pathways, and strategies to make ARID1A-deficient cells a potential therapeutic target for patients with cancer.

Schlagwörter

Stichwörter der Autor:innen

ARID1AEZH2PARPPIK3CAsynthetic lethality

Autor:innen und Institutionen

  • Department of Internal Medicine, HCA Florida Westside Hospital, Plantation, FL, USA.
  • Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Zitieren

APA

Hein, K. Z., Stephen, B., & Fu, S. (2024). Therapeutic Role of Synthetic Lethality in ARID1A -Deficient Malignancies. Journal of Immunotherapy and Precision Oncology, 7(1), 41-52. https://doi.org/10.36401/jipo-22-37

Vancouver

Hein KZ, Stephen B, Fu S. Therapeutic Role of Synthetic Lethality in ARID1A -Deficient Malignancies. Journal of Immunotherapy and Precision Oncology. 2024;7(1):41-52. doi:10.36401/jipo-22-37

BibTeX
@article{Hein2024,
  author = {Hein, Kyaw Z and Stephen, Bettzy and Fu, Siqing},
  title = {Therapeutic Role of Synthetic Lethality in ARID1A -Deficient Malignancies},
  journal = {Journal of Immunotherapy and Precision Oncology},
  year = {2024},
  volume = {7},
  number = {1},
  pages = {41--52},
  doi = {10.36401/jipo-22-37}
}
Kostenlos starten →